Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4337713 · 1 trial · 7 indications
Per investigator assessed Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
| Arm | Type | Description |
|---|---|---|
| LY4337713 (Cohort A1) | EXPERIMENTAL | Escalating doses of LY4337713 administered intravenously (IV). |
| LY4337713 (Cohort A2) | EXPERIMENTAL | Two or more dose regimens of LY4337713 (evaluated during dose escalation) administered IV. |
| Experimental: LY4337713 (Cohort B) | EXPERIMENTAL | Tumor specific cohort will receive LY4337713 administered IV. |
| Experimental LY4337713 (Cohort C) | EXPERIMENTAL | Tumor specific cohort will receive LY4337713 administered IV. |
| Experimental: LY4337713 (Cohort D) | EXPERIMENTAL | Tumor specific cohort will receive LY4337713 administered IV. |
| LY4337713 (Cohort E) | EXPERIMENTAL | Tumor specific cohort will receive LY4337713 administered IV. |
| Name | Type | Description |
|---|---|---|
| LY4337713 | DRUG | Administered IV. |
Inclusion Criteria: * Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment * Must have histologically or cytologically confirmed diagnosis of one of the following: * Adenocarcinoma of the pancreas * Hormone receptor (HR)-positive human e...
LY4337713 is an investigational small molecule being studied for the treatment of ovarian neoplasms. It is also being evaluated in other FAP-positive solid tumors, including breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The drug is currently in Phase 1 clinical development.
LY4337713 targets fibroblast activation protein (FAP), which is expressed in the tumor microenvironment of certain solid tumors. By targeting FAP, the drug aims to treat cancers that are positive for this protein, including ovarian neoplasms and other solid tumors listed in its clinical trial.
LY4337713 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker LLY. The drug is currently in Phase 1 clinical trials for the treatment of FAP-positive solid tumors.
LY4337713 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and efficacy in patients with FAP-positive solid tumors.
LY4337713 is being studied in a Phase 1 clinical trial with the identifier NCT07213791. This trial is recruiting participants with FAP-positive solid tumors, including ovarian neoplasms, and is being conducted in the United States, China, Germany, Japan, and the Netherlands.